↓ Skip to main content

Apixaban for the treatment of saphenous vein graft thrombosis presenting as unstable angina: a case report

Overview of attention for article published in Thrombosis Journal, April 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (52nd percentile)

Mentioned by

twitter
2 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
6 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Apixaban for the treatment of saphenous vein graft thrombosis presenting as unstable angina: a case report
Published in
Thrombosis Journal, April 2017
DOI 10.1186/s12959-017-0133-5
Pubmed ID
Authors

Makoto Saigan, Tsuyoshi Isawa, Tatsushi Ootomo

Abstract

Saphenous vein graft thrombosis can present as unstable angina. However, percutaneous coronary intervention for saphenous vein graft lesions poses a high risk of slow flow related to the procedure. Here we present the utilization of the novel oral anticoagulant, apixaban, in the treatment of unstable angina with extensive saphenous vein graft thrombus, leading to considerable thrombus resolution and eliminating the need of percutaneous coronary intervention. A 72-year-old man with 3-vessel coronary artery bypass graft surgery using a saphenous vein graft and a left internal mammary artery, performed 25 years earlier, presented at our hospital with recurrent chest tightness. The echocardiography showed regional hypokinesis of the post-lateral wall with moderate left ventricular dysfunction, which had not been previously confirmed. Coronary angiography showed obstruction of the saphenous vein graft with a large thrombus burden. The left internal mammary artery was patent and other natives were the same as they had been 3 years ago. He was diagnosed with unstable angina due to acute saphenous vein graft thrombosis. Instead of percutaneous coronary intervention, he was treated with apixaban 5 mg twice a day. The angiography 3 weeks after starting apixaban showed considerable resolution of the thrombus and opening of the saphenous vein graft. Apixaban could become a viable treatment option for acute saphenous vein graft thrombosis.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 33%
Unspecified 1 17%
Student > Bachelor 1 17%
Lecturer 1 17%
Unknown 1 17%
Readers by discipline Count As %
Medicine and Dentistry 3 50%
Pharmacology, Toxicology and Pharmaceutical Science 1 17%
Unspecified 1 17%
Unknown 1 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 April 2017.
All research outputs
#4,763,110
of 9,673,602 outputs
Outputs from Thrombosis Journal
#76
of 130 outputs
Outputs of similar age
#120,448
of 262,409 outputs
Outputs of similar age from Thrombosis Journal
#9
of 9 outputs
Altmetric has tracked 9,673,602 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 130 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,409 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one.